Inclusion Criteria:

To be eligible for participation in this study, subjects must meet all of the following
criteria:

- have been diagnosed with Stage 2, 3 or 4 non-small cell lung cancer or Stage 2, 3 or
4 colorectal cancer or non-hodgkin's lymphoma or chronic lymphocytic leukemia or
Stage 3 or 4 breast cancer.

- be prior to initiation of or between cycles of chemotherapy.

- have experienced greater than or equal to 2% weight loss from the highest patient
reported weight in the 6 months prior to screening for Protocol G200502 (Wt = body
weight)

% weight loss = (Wt at screening - highest Wt in last 6 months) / highest Wt in last
6 months x 100%

- If surgery is part of the cancer treatment, screening for this study should be
conducted at least 2 weeks (14 days) after surgery.

- have a life expectancy of >6 months

- FEMALES - be clinically confirmed as postmenopausal

- MALES - over 45 years of age

- ECOG score ≤1

Exclusion Criteria:

Subjects with any of the following will NOT be eligible for enrollment in this study:

- history of active/uncontrolled congestive heart failure, chronic hepatitis, hepatic
cirrhosis, or HIV infection

- Cardiovascular: No uncontrolled hypertension

- Positive screen for Hepatitis B consisting of HBsAg (Hepatitis B Surface Antigen),
anti-HCV (Hepatitis C Antibody), hepatitis A antibody IgM, or HIV

- Currently taking testosterone, OXANDRIN® (oxandrolone), testosterone-like agents
(such as DHEA, androstenedione, and other androgenic compounds, including herbals),
or antiandrogens (Please note that previous therapy with testosterone and
testosterone-like agents is acceptable with a 30 day wash-out. However, if the
previous testosterone therapy was a long-term depot, within the past 6 months, the
site should call the medical monitor for this study to determine appropriate washout
period.)

- Currently taking megestrol acetate (MEGACE®), dronabinol (MARINOL®), or any
prescription medication intended to increase appetite or treat unintentional weight
loss